槐耳清膏联合肿瘤坏死因子相关凋亡诱导配体对肝癌细胞生长的影响  

Chinese medicine Extractum trametes robiniophila murr augment tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in human hepatic cancer cell lines

作　　者：陈孝平[1] 何松青[1] 赵旭[1] 黄志勇[1] 李常海[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院肝脏外科中心,武汉430030

出　　处：《中华外科杂志》2005年第23期1524-1527,共4页Chinese Journal of Surgery

基　　金：卫生部临床重点学科项目资助(2001)

摘　　要：目的探讨肿瘤坏死因子相关凋亡诱导配体(TRAIL)联合中药槐耳清膏对肝癌细胞株HEPG2及肝癌耐阿霉素(ADM)细胞株(HEPG2-ADM)的作用。方法通过培养液中ADM的浓度梯度递增法筛选培养,建立肝癌细胞HEPG2-ADM耐药细胞株;TRAIL,TRAIL+ADM,TRAIL+槐耳清膏分别处理肝癌细胞株HEPG2、HEPG2-ADM及正常肝细胞株L02,噻唑蓝(MTT)比色法检测细胞增殖,采用流式细胞仪检测细胞凋亡情况。结果联合用TRAIL(100 NG/L)和槐耳清膏(1.0 G/L)处理肝癌细胞株HEPG2-ADM及肝细胞株L02,MTT显示对前者增殖有明显抑制作用,而对后者无明显作用;流式细胞仪检测TRAIL联合槐耳清膏处理HEPG2、HEPG2-ADM,可诱导细胞凋亡,与其他组相比,差异有统计学意义(P<0.05)。结论槐耳清膏可显著增强TRAIL对HEPG2及HEPG2-ADM的杀伤作用,而对正常胎肝细胞株L02杀伤作用轻微,TRAIL和槐耳清膏联合应用可望克服肿瘤细胞中存在的化学治疗药物耐药和TRAIL耐受问题。Objective To investigate the effects of tumor necrosis factor related apoptosis-inducing ligand （TRAIL） combined with Chinese medicine, Extractum trametes robiniophila murr in human hepatic cancer cells. Methods HepG2 cell line resistant to adriamycin （HepG2/ADR） was induced step by step. The effects of TRAIL（ 100 ng/L） combined with Extractum trametes robiniophila murr （ 1.0 g/L） promoting apoptosis in HepG2 or HepG2/ADM were analyzed. The proliferation was observed by M3T assay and the apoptosis of cells was also observed by flow cytometry. Results HepG2/ADM was confirmed resisting to ADM. The treatment of TRAIL（ 100 rig/L） combined with Extractum trametes robiniophila murr （ 1.0 g/L） showed significant inhibitory effects on the growth of both HepG2 and HepG2/ADM, and the percentage of apoptosis was increased compared with other groups within 24 to 72 h. Conclusions Extractum trametes robiniophila murr dramatically augmented the sensitivity of both HepG2 and HepG2/ADM to TRAIL, but only has slightly killing effects on L02. TRAIL combined with Chinese medicine treatment could be a safe and attractive strategy to drug-resistant/TRAIL-resistant tumor cells.

关 键 词：癌 肝细胞 肿瘤坏死因子相关凋亡诱导配体 抗药性 

分 类 号：R735.7[医药卫生—肿瘤]